Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve
Lessons from the ADVANCE Registry

Fairbairn, Timothy A.; Nieman, Koen; Akasaka, Takashi; Nørgaard, Bjarne L.; Berman, Daniel S.; Raff, Gilbert; Hurwitz-Koweek, Lynne M.; Pontone, Gianluca; Kawasaki, Tomohiro; Sand, Niels Peter; Jensen, Jesper M.; Amano, Tetsuya; Poon, Michael; Øvrehus, Kristian; Sonck, Jeroen; Rabbat, Mark; Mullen, Sarah; De Bruyne, Bernard; Rogers, Campbell; Matsuo, Hitoshi; Bax, Jeroen J.; Leipsic, Jonathon; Patel, Manesh R.

Published in:
European Heart Journal

DOI:
10.1093/eurheartj/ehy530

Publication date:
2018

Document version
Final published version

Document license
CC BY

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry


1Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, L14 3PE UK; 2Stanford and Erasmus Medical Center, Rotterdam, Netherlands; 3Wakayama Medical University, 811-1 Kimidiera Wakayama, Wakayama 641-8509, Japan; 4Aarhus University Hospital, Department Cardiology B, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark; 5Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA; 6William Beaumont Hospital, 3601 West 13 Mile Road, Royal Oak, MI 48073, USA; 7Duke University School of Medicine, 2301 Erwin Road, Durham, NC 27710, USA; 8Centro Cardiologico Monzino, IRCCS, University of Milan, Via Carlo Parea 4, 20138 Milan, Italy; 9Shin Koga Hospital, 120 Tenjin-machi, Kurume, Fukuoka 890-8577, Japan; 10University of Southern Denmark, Sdr Boulevard 29, Odense 5000, Denmark; 11Aichi Medical University, 1-1 Yazakakirimata Nagakute, Aichi 480-1195, Japan; 12Northwell Health, 100 E 77th Street, New York, NY 10065, USA; 13UZ Brussels, Laarbeeklaan 101, Brussels 1090, Belgium; 14Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA; 15HeartFlow Inc., 1400 Seaport Blvd, Blvd B, Redwood City, CA 94063, USA; 16Onize-Liew Vrouwenziekenhuis, Moorselbaan 164, Aalst 9300, Belgium; 17Gifu Heart Center, 4-14-4 Yabutamimami, Gifu Gifu 500-8384, Japan; 18Leiden University Medical Center, Albinusdreef 2, Leiden, AZ 2333, Netherlands; and 19Department of Radiology, University of British Columbia, 1081 Burrard Street, Vancouver, BC V6Z1Y6, Canada

Received 29 June 2018; revised 20 July 2018; editorial decision 8 August 2018; accepted 9 August 2018; online publish-ahead-of-print 25 August 2018

See page 3712 for the editorial comment on this article (doi: 10.1093/eurheartj/ehy559)

Aims

Non-invasive assessment of stable chest pain patients is a critical determinant of resource utilization and clinical outcomes. Increasingly coronary computed tomography angiography (CCTA) with selective CCTA-derived fractional flow reserve (FFRCT) is being used. The ADVANCE Registry, a large prospective examination of using a CCTA and FFRCT diagnostic pathway in real-world settings, with the aim of determining the impact of this pathway on decision-making, downstream invasive coronary angiography (ICA), revascularization, and major adverse cardiovascular events (MACE).

Methods and results

A total of 5083 patients with symptoms concerning for coronary artery disease (CAD) and atherosclerosis on CCTA were enrolled at 38 international sites from 15 July 2015 to 20 October 2017. Demographics, symptom status, CCTA and FFRCT findings, treatment plans, and 90 days outcomes were recorded. The primary endpoint of reclassification between core lab CCTA alone and CCTA plus FFRCT-based management plans occurred in 66.9% [confidence interval (CI): 64.8–67.6] of patients. Non-obstructive coronary disease was significantly lower in ICA patients with FFRCT <_0.80 (14.4%) compared to patients with FFRCT >0.80 (43.8%, odds ratio 0.19, CI: 0.15–0.25, P < 0.001). In total, 72.3% of subjects undergoing ICA with FFRCT <_0.80 were revascularized. No death/myocardial infarction (MI) occurred within 90 days in patients with FFRCT >0.80 (n = 1529), whereas 19 (0.6%) MACE [hazard ratio (HR) 19.75, CI: 1.19–326, P = 0.0008] and 14 (0.3%) death/MI (HR 14.68, CI 0.88–246, P = 0.039) occurred in subjects with an FFRCT <_0.80.
Conclusions

In a large international multicentre population, FFR<sub>CT</sub> modified treatment recommendation in two-thirds of subjects as compared to CCTA alone, was associated with less negative ICA, predicted revascularization, and identified subjects at low risk of adverse events through 90 days.

Keywords

**FFRCT** • Coronary CT angiography • Fractional flow reserve • Invasive coronary angiography

Introduction

Coronary computed tomography angiography (CCTA) has been shown to be an effective non-invasive test in the diagnosis and treatment planning for patients with stable chest pain and suspected coronary artery disease (CAD).<sup>1–3</sup> Coronary computed tomography angiography is excellent at ruling out CAD, but its utility is diminished by the limited ability to predict physiologically significant CAD as defined by an abnormal invasive fractional flow reserve (FFR).<sup>4,5</sup>

Coronary computed tomography angiography-derived fractional flow reserve (FFR<sub>CT</sub>) is a non-invasive physiological test that can assess flow limitation across coronary stenoses with high diagnostic accuracy and good correlation to invasive FFR.<sup>6</sup> In addition, FFR<sub>CT</sub> has been shown to reduce the incidence of negative referrals to invasive coronary angiography (ICA) post-CCTA, thus increasing the eventual revascularization rate.<sup>7,8</sup> However, to date most of the data have been limited to single centre populations and trial settings and there remains concerns regarding the clinical application of FFR<sub>CT</sub>, especially in areas of ‘greyzone’ uncertainty, where diagnostic accuracy may be lower.

The Assessing Diagnostic Value of Non-invasive FFR<sub>CT</sub> in Coronary Care (ADVANCE) registry was designed to observe the ‘real-world’ utility and impact of using FFR<sub>CT</sub> in a broad variety of healthcare settings, geographical regions, and patient populations. The study aimed to determine how the incremental information of an anatomical combined with functional FFR<sub>CT</sub> would change clinical decision-making, patient management, clinical outcomes, and resource utilization.

Methods

Patients being investigated for clinically suspected CAD with documented atherosclerosis >30% degree stenosis (DS) on CCTA were prospectively enrolled at 38 sites in Europe, North America, and Japan from 15 July 2015 to 20 October 2017. All subjects were clinically stable symptomatic patients diagnosed with CAD by CCTA who met the following eligibility criteria: age >18 years, ability to provide informed consent, and CAD diagnosed on a diagnostic standard CCTA. Exclusion Criteria included: poor quality CCTA, life expectancy <1 year, and an inability to comply with follow-up requirements. All patients provided written informed consent following Institutional Review Board review and approval. Demographics, symptom status, CCTA and FFR<sub>CT</sub> findings, treatment plans, and clinical outcomes through 90 days were recorded.

Management strategies

The site investigators were asked to report an initial management plan and treatment strategy based on CCTA alone for each subject in accordance with local guidelines for the practice and interpretation of CCTA. The decision to further investigate CCTA results with FFR<sub>CT</sub> was directed by the physician interpreting the scan with a recommendation to consider FFR<sub>CT</sub> for stenoses in the 30–90% range. All FFR<sub>CT</sub> analyses were performed in a single centre (HeartFlow, Redwood City, CA, USA). Once the FFR<sub>CT</sub> result was made available, the site investigators were asked to re-determine the treatment strategy based on the new information of the CCTA combined with the locally interpreted FFR<sub>CT</sub> result. A positive FFR<sub>CT</sub> was deemed to be a value ≤0.80 in accordance with the previous published invasive and non-invasive literature.<sup>9</sup> Subsequent clinical management decisions such as revascularization or medical therapy rested at the discretion of the referring physician. The registry did not dictate interpretation or management decisions.

A core laboratory [Duke Clinical Research Institute (DCRI), Durham, NC, USA] blinded to clinical information, symptom status, and outcomes, reviewed all CCTA and declared an independent management plan based on CCTA alone. Coronary computed tomography angiography-derived fractional flow reserve analyses were then made available to the core lab, who then re-determined the subject specific treatment strategy for each patient based on the CCTA and FFR<sub>CT</sub> results. This involved adjudication of vessel- and lesion-specific ischaemia, measuring the FFR<sub>CT</sub> 2 cm distal to focal lesions.

Management plan treatment strategies for both site and core laboratory consisted of the following options: (i) optimal medical therapy, (ii) percutaneous coronary intervention (PCI), (iii) coronary artery bypass grafting (CABG) surgery, or (iv) additional diagnostic testing required. If revascularization was selected, vessel segments to be revascularized were specified and the interpreter was asked to recommend either PCI or CABG. In instances of high-risk anatomy such as; three-vessel disease, or two vessel involving the left anterior descending (LAD) artery or left main stem disease, a consensus reading of two reviewers determined the appropriate revascularization strategy.

Study endpoints

The primary endpoint was the reclassification rate between CCTA alone vs. CCTA and FFR<sub>CT</sub>-based management plans as determined by the core laboratory. Secondary endpoints included: reclassification rate between CCTA-based and FFR<sub>CT</sub>-based management plans as determined by the site; incidence of ICA demonstrating absence of obstructive CAD (no coronary stenosis >50%); percutaneous and surgical revascularization rates; and 90 days survival free from all cause or major adverse cardiovascular events (MACE) inclusive of myocardial infarction (MI), all-cause mortality or unplanned hospitalization for Acute Coronary Syndrome (ACS) leading to revascularization. Event adjudication was performed by an independent Clinical Events Committee using standard definitions, blinded to clinical, and computed tomographic data.

Statistical analysis

Continuous data are presented as mean (± standard deviation) or median (interquartile range, IQR), categorical data as frequency and percentage. Comparative statistics for net reclassification used the Mann–Whitney and Kruskal–Wallis tests as appropriate. Unpaired t-test was used to determine differences between anatomic severity and rates of positive FFR<sub>CT</sub>. Univariable and multivariable logistic regression models using step-
wise selection were used to estimate the odds of revascularization where a P-value <0.1 was used for entry into the multivariable model. The fit of the final model was assessed using the Log Likelihood and Akaike Information Criterion. The χ² test of independence was used to assess if negative catheterization and MI/death were independent of or associated with minimum FFRCT strata (>0.8/<0.8); in cases of low (expected cell count <5) or zero cell counts, the Fisher’s exact test was used. Odds ratios (ORs) and associated 95% confidence intervals (CIs) were calculated; in cases of zero cell counts, relative risk and associated 95% CIs were calculated. A two-sided level of P < 0.05 was considered significant.

Study funding, design, data gathering, and analysis

The ADVANCE Registry was funded by HeartFlow Inc., via individual Clinical Study Agreements with each enrolling institution and with the DCRI for Core Laboratory activities and Clinical Event Committee adjudication of adverse events. The trial database was housed in iMedNet. HeartFlow and the independent Clinical Research Organization (CRO) had access to iMedNet on the sponsor side. Principal Investigators, sub-investigators, and study co-ordinators at each site had access to iMedNet and were responsible for data entry. The Clinical Event Adjudication and core lab databases were housed in iMedNet. Duke Clinical Research Institute had access to this data for entry, resolving queries, and locking data. The CRO was able to query this data. HeartFlow did not have access to adjudication forms. The primary analysis was performed by the Principal Investigators including Drs Patel, Leipsic, Nieman, and Akasaka, as well as by Dr Fairbairn, with statistical and analytical support from Dr Rogers and Ms Mullen. The manuscript was drafted by the Principal Investigators and Dr Fairbairn. All authors reviewed the manuscript and approved of the submitted manuscript.

Results

Demographic, risk, and coronary artery disease risk factor distribution

Patient demographics and distribution of CAD computed tomography angiography (CTA) findings are provided in Table 1. A total of 5083 patients were enrolled, of whom 4893 had CCTA submitted for FFRCT (96.2%). A total of 190 subjects did not have their CCTA examinations submitted for FFRCT analysis at the site discretion: 111 because the invasive treatment decision was made due to the severity of the stenosis; 61 owing to minimal CAD; 9 because of multiple coronary stents; 2 because of CCTA exams not acquired in a fashion acceptable for FFRCT analysis. Of the submitted CCTAs 4737 (96.8%) were of adequate quality for analysis. 3.2% were rejected from FFRCT analysis because of image quality. Angina (typical or atypical) was the predominant symptom in 58%, with an average Diamond–Forrester pre-test probability for obstructive coronary disease of 51.6%. There

<p>| Table 1 Demographics, coronary artery disease risk factors, and symptom status |
|---------------------------------|------------------|------------------|------------------|</p>
<table>
<thead>
<tr>
<th>CTA only (n = 346)</th>
<th>FFRCT (n = 4737)</th>
<th>Total (n = 5083)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64.3 (11.1)</td>
<td>66.1 (10.3)</td>
</tr>
<tr>
<td>Male gender</td>
<td>215 (62.1%)</td>
<td>3134 (66.2%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>210 (60.7%)</td>
<td>2835 (59.8%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>99 (28.6%)</td>
<td>1017 (21.9%)</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>204 (59%)</td>
<td>2753 (58.1%)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoking</td>
<td>46 (13.3%)</td>
<td>797 (16.8%)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>118 (34.1%)</td>
<td>1615 (34.1%)</td>
</tr>
<tr>
<td>Never smoked</td>
<td>141 (41.6%)</td>
<td>1973 (41.7%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>38 (11.0%)</td>
<td>352 (7.4%)</td>
</tr>
<tr>
<td>Angina status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atypical</td>
<td>175 (50.6%)</td>
<td>1727 (36.5%)</td>
</tr>
<tr>
<td>Typical</td>
<td>41 (11.8%)</td>
<td>1025 (21.6%)</td>
</tr>
<tr>
<td>Non-cardiac pain</td>
<td>8 (2.3%)</td>
<td>297 (6.3%)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>34 (9.8%)</td>
<td>472 (10.0%)</td>
</tr>
<tr>
<td>None</td>
<td>73 (21.1%)</td>
<td>1164 (24.6%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>15 (4.3%)</td>
<td>52 (1.1%)</td>
</tr>
<tr>
<td>CCS angina class</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>18 (43.9%)</td>
<td>254 (24.8%)</td>
</tr>
<tr>
<td>Grade II</td>
<td>16 (39.0%)</td>
<td>561 (54.7%)</td>
</tr>
<tr>
<td>Grade III</td>
<td>5 (12.2%)</td>
<td>111 (10.8%)</td>
</tr>
<tr>
<td>Grade IV</td>
<td>0</td>
<td>23 (2.2%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (4.9%)</td>
<td>76 (7.4%)</td>
</tr>
<tr>
<td>CCTA rejection rate</td>
<td></td>
<td>160 (3.1%)</td>
</tr>
<tr>
<td>Diamond–Forrester risk</td>
<td>46.8 (±19.9)</td>
<td>51.6 (±20.3)</td>
</tr>
</tbody>
</table>

CTA, computed tomography angiography.
Figure 1  Degree of coronary artery disease (% stenosis) and coronary computed tomography angiography-derived fractional flow reserve positive/negative ratio stratified by coronary artery territory: (A) left anterior descending; (B) left circumflex, and (C) right coronary artery.
was no significant difference between subject group demographics or risk factors for those receiving CCTA alone vs. CCTA plus FFRCT.

**Extent and severity of coronary artery disease by coronary computed tomography angiography and coronary computed tomography angiography-derived fractional flow reserve**

Coronary atheroma $>50\%$ DS was observed at CCTA in 72.1\% of subjects ($n=3398$) and $>70\%$ DS in 32\% ($n=1538$). Two- or three-vessel disease ($>50\%$ DS) was present in 27.5\% and 9.4\%, respectively. Ischaemia (FFR$_{CT} \leq 0.80$) in at least one coronary territory was present in 61.9\% ($n=3145$) of patients (Figure 1). The LAD was more likely to have anatomically severe ($>70\%$ DS), coronary disease (21.4\%), and a positive FFRCT ($n=2760, 58.3\%$) compared with other vessels: left circumflex (LCX) 23.8\% ($n=1260$), right coronary artery (RCA) 22.1\% ($n=1047$) ($P < 0.001$). The LAD exhibited significantly lower median FFRCT values (0.79: IQR 0.71–0.85) compared with the LCX (0.88: IQR 0.81–0.92) and RCA (0.87: IQR 0.82–0.91) ($P < 0.001$). However, a positive FFRCT in the mild-moderate (30–70%) stenosis range was more likely in the LAD (55.3\%) compared with LCX (31.7\%) and RCA (27.3\%) ($P < 0.001$).

**Figure 2** Clinical management strategies and reclassification of post-coronary computed tomography angiography, following coronary computed tomography angiography-derived fractional flow reserve and actual management at 90 days (A Core and B Site).
Recommended clinical management strategies following coronary computed tomography angiography-derived fractional flow reserve

Coronary computed tomography angiography-derived fractional flow reserve resulted in revision of the clinical management plan as determined by the site investigators in 63.5% of patients (CI: 62.0–65) when compared with initial CCTA-based treatment plan. Under core laboratory analysis, FFRCT changed management plans in 66.9% of patients (CI: 64.8–67.6). Reclassification patterns are shown in Figure 2. Of 2386 (59.7%) patients in whom further information was required after CCTA, FFRCT reclassified 70.0% (n = 1671) to medical treatment (MT), 24.4% (n = 570) to PCI, 2.1% (n = 49) to CABG, and only 2.6% (n = 121) were assigned to downstream testing. An initial management decision for MT was assigned to 19.2% (n = 790), and this assignment remained unchanged after FFRCT in 93% of cases, with only 5.4% changing to revascularization (Table 2 and Figure 3). However, among the 22.9% of subjects (n = 943) for whom the CCTA-based management plan indicated revascularization, 22.3% were reclassified to MT alone after FFRCT analysis (PCI to MT 20.9%, n = 198; CABG to MT 1.4%, n = 12). A positive FFRCT (≤0.80)
occurred in 61.9% of subjects, yet only 34.4% (site) and 46.8% (core) of cases were recommended for revascularization despite the majority of these patients; 69.5% (n = 984) having anatomically significant disease (>50% DS) on CCTA. Over half of the deferrals from ICA, 53.9% (n = 762) had an FFRCT between 0.75 and 0.8, with patients with lower FFRCT more likely to be recommended for ICA (Table 3).

**Rate of non-obstructive angiography and revascularization**

The rate of anatomically defined ‘non-obstructive’ disease at ICA (no stenosis >50% at ICA) was significantly lower in patients with FFRCT \( <0.80 \) (14.4%) vs. FFRCT \( >0.80 \) (43.8%), (OR 0.15–0.25, \( P < 0.001 \)) (Figure 3).

When stratified by 0.05 categorical FFRCT increments, subjects were significantly more likely to undergo ICA with decreasing FFRCT (FFRCT \( \leq 0.70 \): 73.8% vs. FFRCT \( >0.80 \): 20.5%) and to be revascularized at ICA (FFRCT \( \leq 0.70 \): 72.5% vs. FFRCT \( >0.80 \): 20.4% \( P < 0.001 \)), (Supplementary material online). In multivariable analysis, stenosis \( >70\%/\text{occluded vessel} \) (OR 5.85–6.36, \( P < 0.001 \)) and FFRCT \( <0.80 \) (OR 5.88, \( P < 0.001 \)) were significant predictors of revascularization (Table 4 and Figure 4), as were the presence of typical/atypical symptoms and male gender.

**Major adverse cardiovascular events, myocardial infarction, and death**

No death or MI occurred within 90 days in any subject whose FFRCT was \( >0.80 \) (\( n = 1592 \)). Conversely, in patients with at least one FFRCT value \( \leq 0.80 \) (\( n = 3145 \)) there were 19 (0.6%, \( P < 0.01 \)) MACE events; 4 MI, 5 urgent unplanned hospitalizations for ACS and urgent revascularization and 10 deaths. These events predominantly occurred in the lower FFRCT ranges below 0.76 (18 of 19), indicating that an FFRCT \( \leq 0.80 \) increased the risk of an adverse event [MACE, hazard ratio (HR) 19.75, CI 1.19–326, \( P = 0.0008 \) and 14 death/MI, HR 14.68, CI 0.88–246, \( P = 0.039 \)], (Figure 5A and B).

**Discussion**

In this large prospective international multicentre registry, FFRCT changed management recommendations from CCTA-based plans in approximately two out of three subjects. A negative FFRCT was associated with a low rate of invasive angiography or revascularization within 90 days and with freedom from MI or death. In addition, there was an inverse relationship between FFRCT and the likelihood of downstream ICA, revascularization, and MACE.

Coronary computed tomography angiography is now considered a reasonable or preferred first line investigation for patients with suspected CAD,\(^{12–14}\) as studies have suggested improved clinical outcomes for patients managed based on initial CCTA rather than alternative non-invasive tests.\(^{4}\) While, CCTA has been proven to be an effective diagnostic tool, there remain concerns regarding fairly high rates of downstream ICA and resource utilization as well as the lack of physiological information available to guide treatment decision-making.\(^{2,15,16}\) FFRCT has been proposed as a diagnostic tool to help determine more appropriately who should proceed for ICA following CCTA.\(^{7,15,17}\) The PROMISE FFRCT retrospective sub-study highlighted the potential of FFRCT to reduce ICA referral and enrich the appropriateness of the population referred for ICA.\(^{17,18}\)

Our findings based on prospective utilization of FFRCT after positive CCTA represent the first real-world multicentre evaluation of the utility and safety of FFRCT. FFRCT led to a recommendation of ICA in only 40% of subjects in a cohort with an anatomic obstructive disease rate of 72%, and subjects referred for ICA downstream were significantly more likely to have obstructive disease at ICA if they had a positive FFRCT.\(^{19–21}\)

Management reclassification by FFRCT as expected occurred in all directions. There was, however, a clear directed benefit in instances of physician uncertainty expressed by the need for ‘further testing’, as the majority of subjects (70%) were safely deferred to medical management alone. Importantly only in a very small minority of cases (0% by core lab and 2.6% by site) was further testing deemed necessary to determine CAD significance, thereby highlighting the improved diagnostic certainty and the opportunity to reduce further downstream testing. Importantly, this approach of test layering not only results in increased costs and at times additional radiation exposure, it may not help discriminate those patients likely to benefit from revascularization. In the recently published PACIFIC trial, hybrid testing with a CTA/SPECT approach did not enhance on the accuracy for the detection of lesions specific ischaemia beyond CCTA or SPECT alone.\(^{22}\) In instances, when the physician recommendation was for revascularization post-CCTA alone, FFRCT redirected management to medical therapy in close to 25% of cases, offering the potential to avoid unnecessary ICA. This observation supports the concept that CCTA alone could result in increased ICA without revascularization.\(^{6}\) Interestingly a positive FFRCT \( <0.80 \) was not

**Table 4**  Multivariable logistic regression analysis of univariate predictors of revascularization amongst subjects with coronary computed tomography angiography-derived fractional flow reserve performed as compared to those subjects who did not undergo revascularization

<table>
<thead>
<tr>
<th>Covariates</th>
<th>Estimates of effect</th>
<th>Odds ratio</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (≥65)</td>
<td>-0.0433</td>
<td>0.96 (0.81–1.14)</td>
<td>0.6189</td>
</tr>
<tr>
<td>Female gender</td>
<td>-0.2953</td>
<td>0.74 (0.62–0.90)</td>
<td>0.0023</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>0.3036</td>
<td>1.35 (1.14–1.61)</td>
<td>0.0005</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.0990</td>
<td>1.10 (0.91–1.33)</td>
<td>0.3066</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.1150</td>
<td>1.12 (0.89–1.41)</td>
<td>0.3189</td>
</tr>
<tr>
<td>Symptom status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Typical angina</td>
<td>0.9898</td>
<td>2.69 (2.14–3.38)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Atypical angina</td>
<td>0.2808</td>
<td>1.32 (1.06–1.61)</td>
<td>0.0129</td>
</tr>
<tr>
<td>Non-cardiac pain</td>
<td>0.1223</td>
<td>1.13 (0.76–1.89)</td>
<td>0.5400</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>0.3204</td>
<td>1.38 (1.00–1.89)</td>
<td>0.0472</td>
</tr>
<tr>
<td>Coronary stenosis &gt;70%</td>
<td>1.7666</td>
<td>5.85 (4.95–6.91)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FFRCT &lt;0.8</td>
<td>1.8959</td>
<td>5.88 (4.43–7.80)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

followed by either ICA or revascularization in up to half of cases, despite the majority having evidence of anatomical (>50% DS) significant disease. This perhaps reflects nuanced management decisions regarding factors such as diffuse atherosclerosis and the absence of lesion specific ischaemia or other factors such as anatomical location, comorbidities, and symptom severity. It is also important to recognize that follow-up is limited to 90 days at present and longer term follow-up will be valuable to assess whether these medically managed FFR_{CT}-positive patients will end up needing revascularization over time is uncertain. These findings should also be placed into the context of recent guidelines highlighting the importance of guiding revascularization decision-making based on anatomy and physiology emphasizing the value of FFR_{CT} to enable meaningful Heart Team discussions in a fashion that CTA alone cannot.\textsuperscript{23,24}

There is also growing awareness that while in a trial setting FFR and FFR_{CT} have been evaluated using a binary cut-off, in practice the benefit from revascularization seems to increase with lower FFR values.\textsuperscript{21,25,26} Predictors of revascularization in this study were lesion specific ischaemia by FFR_{CT}, diameter stenosis $\geq 70\%$ and angina

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{Major adverse cardiac events (A) (all-cause mortality, myocardial infarction, unplanned hospitalization with urgent revascularization) and (B) myocardial infarction/all-cause mortality alone at 90 days for coronary computed tomography angiography-derived fractional flow reserve positive ($\leq 0.80$) and negative values ($>0.80$).} 
\end{figure}
symptoms. FFR\textsubscript{CT}, like all test results, needs to be integrated into the overall clinical presentation including severity of symptoms. There was a difference noted between site and core management plans in the setting of positive FFR\textsubscript{CT}, with site management strategies being more conservative in recommending ICA and revascularization (34.4%), supporting the theory that there is a significant role in the interpretation and clinical context of the FFR\textsubscript{CT} result, as sites were privy to greater information of the clinical history and co-morbidities whereas the core lab was not.

This international real-world registry has also highlighted patterns of physician referral behaviour. The majority of lesions referred for further investigation were in the LAD, which is greater than the observed proportions of LAD disease burden in ICA studies,\textsuperscript{19} and likely reflects heightened clinical concerns owing to the prognostic importance of LAD disease. The varied correlation between degree of stenosis and ischaemia is well known from studies such as FAME and RIPCORD,\textsuperscript{27,28} which may result in a higher degree of uncertainty and desire to know more information. The increased likelihood of FFR\textsubscript{CT}-determined ischaemia in the mild-moderate (30–70%) degree of anatomical stenosis in the LAD compared to other vessels is of particular diagnostic use and given the high frequency in our patient population (55.3%), justifies clinicians’ vigilance in referring these lesions to ICA.\textsuperscript{24,25}

Beyond defining the clinical use and role of FFR\textsubscript{CT}, our data provide meaningful insight into the potential prognostic value of FFR\textsubscript{CT} in clinical practice. Importantly, a negative FFR\textsubscript{CT} was associated with an excellent short-term prognosis, as none of the 1592 subjects with negative FFR\textsubscript{CT} experienced death, MI, or unplanned hospitalization for ACS and urgent revascularization. All MACE events occurred in subjects with FFR\textsubscript{CT} $\leq 0.80$, with the majority of events in subjects with an FFR\textsubscript{CT} $\leq 0.75$. This clustering of events in subjects with more significant ischaemia is interesting, however, long-term clinical follow-up is needed to determine if there is a relationship between the severity of FFR\textsubscript{CT} reduction and adverse clinical outcomes. Our results mirror the invasive physiology experience where lower FFR values have been consistently shown to predict all-cause mortality and increased likelihood of MI and urgent revascularization.\textsuperscript{29}

**Limitations**

Our analysis is not without limitations. To start, while including a broad sampling of patients undergoing FFR\textsubscript{CT} across many countries and healthcare systems, ADVANCE is a registry, and therefore, we cannot exclude some element of referral bias. As well, while sites provided their treatment strategies on the basis of CCTA, virtually all subjects had FFR\textsubscript{CT} available and therefore what their downstream treatment would have been in absence of FFR\textsubscript{CT} cannot be determined with complete certainty. As such, while we report the change in clinical recommendations following FFR\textsubscript{CT} as compared to CCTA alone, through 90 days not all site recommendations were followed clinically, highlighting the multifaceted nature of clinical decision-making. In addition, while detailed case/incident reports were submitted detailing all events, like many registries, a central event adjudication committee was not used. Finally, the Follow-up reported represents only the first 90 days, and although most adverse events and invasive management strategies occur within this time, longer term follow-up is essential particularly for MACE, and therefore is planned through 3 years in the ADVANCE registry.

**Conclusions**

In a large international multicentre population, FFR\textsubscript{CT}-modified treatment recommendation in up to two-thirds of subjects as compared to CCTA alone, was associated with fewer ICA without obstructive disease, and predicted revascularization, while helping discriminate subjects at lower risk of adverse events at 90 days.

**Supplementary material**

Supplementary material is available at *European Heart Journal* online.
Funding
This study was supported by HeartFlow, Inc., Redwood City, CA, USA, via individual Clinical Study Agreements with each enrolling institution and with the Duke Clinical Research Institute (DCRI) for Core Laboratory activities and Clinical Event Committee adjudication of adverse events.

Conflict of interest: T.A.F. is on the speaker's bureau for HeartFlow. K.N. has received unrestricted institutional research grants from Siemens, Bayer, GE, and HeartFlow. B.L.N. has received unrestricted institutional research grants from Siemens and HeartFlow. D.S.B. has received unrestricted research support from HeartFlow. G.P. received institutional research grant and/or honorarium as consultant/speaker from GE Healthcare, Bracco, Medtronic, Bayer, HeartFlow. B.D.B. receives consulting fees from Abbott, Opsens, and Boston Scientific and is a shareholder for Siemens, GE, Bayer, Philips, HeartFlow, Edwards Life Sciences, and Sanofi. C.R. is an employee of and has equity in HeartFlow. S.M. is an employee of and has equity in HeartFlow. J.L. is a consultant for and has stock options in Circle CVI and HeartFlow. M.R.P. has received grants from HeartFlow, Jansen, Bayer, Astra Zeneca, and NHLBI and served as a consultant for Jansen, Bayer, Astra Zeneca, Genzyme, and Merck. M.R. is a consultant for HeartFlow. L.H.-K. has received research support and speaking fees from HeartFlow and Siemens.

References


